Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer
(NASDAQ:OLMA) SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the ...
What are the financial terms of the Pfizer supply agreement and could it lead to dilution, milestone payments, or significant cash inflows for Olema?
How does the palazestrant + atirmociclib combination compare to existing ER+/HER2‑ therapies and competing pipelines in terms of efficacy and market potential?
What is the expected timeline for trial readout and how might it drive short‑term volatility in Olema's stock?
Symbol:
OLMA
4 days ago